Summary: Immunovia’s new test for pancreatic cancer could help set a high standard in early detection and efficient diagnostics within the IVD sector.

Takeaways:

  • The IMMray PanCan-d test demonstrated a specificity of 98% and a sensitivity of 75% for early stage 1 and 2 pancreatic cancers 
  • Immunovia’s test was shown to outperform the commonly used CA19-9 biomarker, which some patients cannot produce, thereby expanding the test’s applicability.
  • Immunovia’s test is part of a larger shift towards more accurate and early diagnostics, with a planned launch in 2025 promising to advance patient care in oncology.

Immunovia announced promising results for its latest pancreatic cancer diagnostic test in a clinical trial, where it demonstrated a specificity of 98% and a sensitivity of 75% for early stage 1 and 2 pancreatic cancers 

With the demand for early disease diagnosis and a transformative shift towards accuracy and efficiency for in vitro diagnostics (IVD), Immunovia’s new test contributes to the sector’s increasingly crucial role in preventive healthcare and early disease detection, according to GlobalData, a leading data and analytics company. 

The Growing Oncology Diagnostics Department

“The market for oncology tests in IVD is witnessing significant growth and diversification. The growth of the market is supported primarily by the continuous increase in cancer prevalence due to the aging population and changing lifestyles,” says Cynthia Stinchcombe, Medical Devices Analyst at GlobalData. “GlobalData projects that with the continuous advancements in technology and the introduction of innovative therapies, the landscape of oncology diagnostics is set to transform, offering new hope to millions affected by cancer.”

Immunovia’s Pancreatic Cancer Test

Immunovia’s test outperforms the commonly used CA19-9 biomarker, which some patients cannot produce, thereby expanding the test’s applicability to a broader patient demographic, according to GlobalData. Immunovia is preparing for further studies, including a second phase of the model development and several analytical validation steps, aiming for a full clinical validation and a planned launch in 2025.

“The advancements in oncology diagnostics, fueled by companies like Immunovia, signify a major step forward in the accurate and early detection of cancer,” Stinchcombe says. “With the industry focusing on both established and emerging diagnosis options, the scope for oncology diagnostics is widening, offering a brighter future for those affected by these conditions.”

Evolving Pancreatic Testing Landscape

GlobalData’s analysis underscores the importance of innovative diagnostic methods in the evolving oncology diagnostics landscape, highlighted by Immunovia’s advancement with its next-generation IMMray PanCan-d test for pancreatic cancer. This test significantly enhances early detection capabilities with superior sensitivity and specificity compared to traditional biomarkers like CA19-9. 

Further reading: Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis

Leveraging Immunovia’s expertise in molecular diagnostics and antibody microarray technology, the IMMray PanCan-d test broadens patient accessibility and promises improved outcomes by detecting pancreatic cancer at more treatable stages, setting a new standard in the field, says GlobalData.

“Amidst an aging population and the increasing prevalence of pancreatic cancer, the progress being made is not just promising; it is a beacon of hope for patients,” says Stinchcombe. “The dynamic expansion of the IVD market, driven by relentless innovation and research, marks a hopeful era for patients.”